Alteminostat CKD-581|cas:1246374-97-9|西域试剂

Alteminostat CKD-581,98.66%

产品编号：Bellancom-109109| CAS NO：1246374-97-9| 分子式：C₂₇H₃₆N₆O₃| 分子量：492.61

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-109109	￥4500.00	杭州北京（现货）
Bellancom-109109	￥7000.00	杭州北京（现货）
Bellancom-109109	￥14800.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

Alteminostat CKD-581

产品介绍

Alteminostat (CKD-581) 是一种有效的 HDAC 抑制剂。Alteminostat 通过组蛋白 H3 和微管蛋白乙酰化抑制 I-II 类 HDAC 家族。Alteminostat 可用于淋巴瘤和多发性骨髓瘤的研究。

生物活性

Alteminostat (CKD-581) is a potent HDAC inhibitor. Alteminostat inhibits the class I-II HDAC family via histone H3 and tubulin acetylation. Alteminostat can be used for lymphoma and multiple myeloma research.

体外研究

Alteminostat (CKD-581; 1 nM-10 μM; 72 hours) treatment potently reduces cell viability in all four lymphoma cell lines in a concentration-dependent manner. The IC50 values of Alteminostat in SU-DHL-4, OCI-LY1, SU-DHL-2, and U2932 cells are 1.31 nM, 36.91 nM, 1.18 nM, and 31.99 nM, respectively.
Alteminostat (CKD-581; 10-300 nM; 24 hours) treatment decreases the expression of BCL-6 as well as BCL-2 in cells.
Alteminostat (CKD-581; 30-300 nM; 24 h) treatment results in γH2AX accumulation and PARP1 cleavage in SU-DHL-4, OCI-LY1, SU-DHL-2, and U2932 cells. Alteminostat decreases the protein levels of BCL-XL and MCL-1 in a concentration-dependent manner in OCI-LY1 cells.
Alteminostat (CKD-581; 10-300 nM; 6 hours) treatment increases the acetylation of histone H3 in SU-DHL-2 cells. And tubulin acetylation also increased with 10 nM CKD-581. CKD-581 increased the acetylation of target molecules by inhibiting class I-II HDACs in lymphoma cells.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay

Cell Line:	SU-DHL-4, OCI-LY1, SU-DHL-2, and U2932 cells
Concentration:	1 nM-10 μM
Incubation Time:	72 hours
Result:	Potently reduced cell viability in all four lymphoma cell lines in a concentration-dependent manner.

Western Blot Analysis

Cell Line:	SU-DHL-4 and OCI-LY1 cells
Concentration:	10 nM, 30 nM, 100 nM, 300 nM
Incubation Time:	24 hours
Result:	Decreased the expression of BCL-6 as well as BCL-2 in cells.

体内研究
(In Vivo)

Alteminostat (CKD-581; 20-40 mg/kg; ntraperitoneal injection; twice a week; for 4 weeks) treatment partially but significantly suppresses tumor growth in SU-DHL-4 xenograft mice.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male NOD.CB17 SCID injected with SU-DHL-4 cells
Dosage:	20 mg/kg or 40 mg/kg
Administration:	Intraperitoneal injection; twice a week; for 4 weeks
Result:	Partially but significantly suppressed tumor growth.

体内研究

Alteminostat (CKD-581; 20-40 mg/kg; ntraperitoneal injection; twice a week; for 4 weeks) treatment partially but significantly suppresses tumor growth in SU-DHL-4 xenograft mice.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male NOD.CB17 SCID injected with SU-DHL-4 cells
Dosage:	20 mg/kg or 40 mg/kg
Administration:	Intraperitoneal injection; twice a week; for 4 weeks
Result:	Partially but significantly suppressed tumor growth.

体内研究

Alteminostat (CKD-581; 20-40 mg/kg; ntraperitoneal injection; twice a week; for 4 weeks) treatment partially but significantly suppresses tumor growth in SU-DHL-4 xenograft mice.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male NOD.CB17 SCID injected with SU-DHL-4 cells
Dosage:	20 mg/kg or 40 mg/kg
Administration:	Intraperitoneal injection; twice a week; for 4 weeks
Result:	Partially but significantly suppressed tumor growth.